US EditionAscletis Reports Positive U.S. Phase Ib Results for ASC30, Submits Phase IIa Protocol to FDA
- Ascletis Pharma announced positive topline results from a U.S. Phase Ib study of its ASC30 oral tablet on April 22, 2025.
- The randomized, double-blind, placebo-controlled multiple ascending dose study evaluated ASC30 in obese participants.
- This four-week trial included three cohorts testing different weekly dose titration schemes.
- One titration scheme achieved 4.3% mean body weight reduction after four weeks of treatment.
- Results support a lower dose strategy and informed the planned U.S. Phase IIa study design submitted to FDA.
30 Articles
30 Articles
Bennington Banner
Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA
ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 mg doses.
Ascletis Reports Positive U.S. Phase Ib Results for ASC30, Submits Phase IIa Protocol to FDA
HONG KONG, April 23, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today positive topline results of its randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study (NCT06680440), conducted in the U.S., of ASC30 oral once-daily tablet in participants with obesity (body mass index (BMI): 30-40 kg/m2). The Phase Ib MAD study consisted of three cohorts, each with a different weekly titrati…
Coverage Details
Bias Distribution
- 87% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
